Over Half of GLP-1 Users Report Side Effects
More than half of patients on GLP-1 drugs like Ozempic and Wegovy reported seeking follow-up medical care for side effects, a new survey from Phenomix Sciences found. The report highlights that real-world outcomes and tolerability vary widely, reinforcing the need for more personalized approaches to obesity care beyond just prescribing the medication.
Gastrointestinal issues are the most frequently reported side effects of GLP-1 agonists, driven by the drug's mechanism of slowing down how quickly food leaves the stomach. This delayed gastric emptying helps with satiety but can also trigger nausea, vomiting, constipation, and diarrhea, particularly when first starting the medication or increasing the dose. The prevalence of these side effects is significant; a meta-analysis of multiple clinical studies estimated that between 40% and 70% of people using GLP-1 drugs will experience nausea at some point. For the medication liraglutide, up to 40% of patients report nausea, leading as many as 6.4% to discontinue the treatment altogether. This variability in patient response highlights a critical need for personalization. Companies are now using machine-learning algorithms to address this. By analyzing a patient's genetic profile with a Genetic Risk Score (GRS), it's possible to predict who is more than twice as likely to experience nausea on certain GLP-1s before they even start the medication. This predictive capability opens the door for AI-powered consumer health apps to provide proactive, personalized support. Such apps can use machine learning to analyze user-reported symptoms and data from wearables to identify patterns, helping users manage side effects by suggesting specific dietary changes, meal timing, and other behavioral adjustments. For a startup in this space, user acquisition strategies employed by apps like Noom and BetterMe are key, focusing on web-based funnels that target high-intent users with specific goals, such as managing a condition or a side effect. Building trust is paramount, which can be achieved by offering educational content and demonstrating clear progress, turning free users into paying subscribers. However, founders must navigate a complex privacy landscape. Most consumer health apps are not directly covered by HIPAA; instead, they fall under the FTC's Health Breach Notification Rule and a patchwork of state privacy laws. This puts the responsibility on the developer to ensure transparent data handling and robust security to build and maintain user trust. The journey from developer to CEO in digital health involves reconciling the tech mantra of "move fast and break things" with healthcare's core principle of "do no harm." Success requires a collaborative spirit and deep understanding of the patient experience, transforming technical expertise into tools that empower users on their health journey.
